Humanwell Healthcare Group Co Ltd banner

Humanwell Healthcare Group Co Ltd
SSE:600079

Watchlist Manager
Humanwell Healthcare Group Co Ltd Logo
Humanwell Healthcare Group Co Ltd
SSE:600079
Watchlist
Price: 18.6 CNY 0.05%
Market Cap: ¥30.4B

P/OCF

12.1
Current
22%
Cheaper
vs 3-y average of 15.4

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
12.1
=
Market Cap
¥30.9B
/
Operating Cash Flow
¥2.5B

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
12.1
=
Market Cap
¥30.9B
/
Operating Cash Flow
¥2.5B

Valuation Scenarios

Humanwell Healthcare Group Co Ltd is trading below its 3-year average

If P/OCF returns to its 3-Year Average (15.4), the stock would be worth ¥23.7 (27% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+107%
Average Upside
54%
Scenario P/OCF Value Implied Price Upside/Downside
Current Multiple 12.1 ¥18.6
0%
3-Year Average 15.4 ¥23.7
+27%
5-Year Average 15.8 ¥24.36
+31%
Industry Average 25 ¥38.59
+107%
Country Average 18.3 ¥28.17
+51%

Forward P/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward P/OCF

Peer Comparison

All Multiples
P/OCF
P/E
All Countries
Close
Market Cap P/OCF P/E
CN
Humanwell Healthcare Group Co Ltd
SSE:600079
30.4B CNY 12.1 16.4
US
Eli Lilly and Co
NYSE:LLY
825.8B USD 49.1 40
US
Johnson & Johnson
NYSE:JNJ
548.5B USD 22.4 26.1
CH
Roche Holding AG
SIX:ROG
248.4B CHF 13.7 20.1
UK
AstraZeneca PLC
LSE:AZN
215.6B GBP 19.6 27.9
CH
Novartis AG
SIX:NOVN
218.9B CHF 14.3 19.6
US
Merck & Co Inc
NYSE:MRK
272.3B USD 16.5 14.9
IE
Endo International PLC
LSE:0Y5F
244.4B USD 907.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 9.9 11.5
US
Pfizer Inc
NYSE:PFE
150.6B USD 12.9 19.4
US
Bristol-Myers Squibb Co
NYSE:BMY
117.3B USD 8.3 16.6
P/E Multiple
Earnings Growth PEG
CN
Humanwell Healthcare Group Co Ltd
SSE:600079
Average P/E: 21.3
16.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26.1
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.9
25%
1.1
CH
Novartis AG
SIX:NOVN
19.6
14%
1.4
US
Merck & Co Inc
NYSE:MRK
14.9
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.4
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.6
16%
1

Market Distribution

In line with most companies in China
Percentile
36th
Based on 6 232 companies
36th percentile
12.1
Low
0.2 — 9.8
Typical Range
9.8 — 36.5
High
36.5 —
Distribution Statistics
China
Min 0.2
30th Percentile 9.8
Median 18.3
70th Percentile 36.5
Max 266 666.7

Humanwell Healthcare Group Co Ltd
Glance View

Market Cap
30.4B CNY
Industry
Pharmaceuticals

In the rapidly evolving landscape of the Chinese pharmaceutical industry, Humanwell Healthcare Group Co Ltd. stands as a multifaceted player with its roots deeply embedded in both innovation and tradition. Founded in Wuhan, Humanwell has cultivated a robust portfolio that extends beyond the manufacture and distribution of pharmaceuticals, marking its presence in fields like anesthetics, reproductive health products, and specialty chemicals. Anchoring its operations is a commitment to research and development, investing significantly in new technologies and drug formulations. Humanwell leverages its extensive manufacturing capabilities and adheres to rigorous quality controls, enabling it to efficiently produce and market a diverse array of products across domestic and international markets. The company’s financial structure is bolstered by a savvy integration of its capabilities and strategic partnerships, enhancing both its market reach and product offerings. With subsidiaries spread across different continents, Humanwell taps into the lucrative supply chains of the healthcare sector, accentuating its revenue streams. Through strategic acquisitions and partnerships, the company has invested in expanding its global footprint, enhancing its competitive prowess. This tactical expansion, coupled with a keen focus on understanding and fulfilling consumer needs, allows Humanwell Healthcare not only to sustain a strong financial performance but also to play a pivotal role in shaping the future of the healthcare market in China and beyond.

Intrinsic Value
30.38 CNY
Undervaluation 39%
Intrinsic Value
Price ¥18.6
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett